# A Safety Study of LY3462817 in Healthy Participants

> **NCT03715192** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** LY3462817 IV
- **BIOLOGICAL:** LY3462817 SC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03715192
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2019-12-11
- **Final completion:** 2019-12-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715192, "A Safety Study of LY3462817 in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03715192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*